Summit’s DMD drug cuts muscle inflammation in POC trial

Duchenne muscular dystrophy
Histopathology of gastrocnemius muscle from a DMD patient (Dr. Edwin P. Ewing, Jr./Public domain)

Summit Therapeutics has posted further data from the ongoing phase 2 trial of ezutromid. The latest analysis links the utrophin modulator to a statistically significant decline in muscle inflammation in boys with Duchenne muscular dystrophy (DMD).

Oxford, U.K.-based Summit generated the data on muscle inflammation by measuring MRI transverse relaxation time T2 (MRS-T2). The technique quantifies the breakdown and inflammation of muscle, making it a useful tool for assessing the progression of DMD. MRS-T2 values rise as DMD progresses but can be brought down by steroids.

The Summit data suggest ezutromid may drive reductions in MRS-T2 beyond those achieved by the use of steroids alone. All 38 participants in the proof-of-concept trial were on stable steroid regimes. After 24 weeks of twice-daily ezutromid doses, MRS-T2 decreased by 0.861 milliseconds, on average.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Summit needs to do more work to show whether that finding and others generated to date have a meaningful effect on the lives of people with DMD. But some observers see the data gathered so far as a source of encouragement.

“The decrease in MRS-T2 seen in PhaseOut DMD is encouraging and suggests ezutromid is having a positive effect on muscle health,” H. Lee Sweeney, director of the Myology Institute at the University of Florida, said in a statement. “These data could be an early indication that these patients are experiencing a decrease in disease severity and highlight ezutromid's potential as a disease modifying treatment.”

RELEASE: Summit Therapeutics unveils encouraging early data for Duchenne drug

Publication of the data on MRS-T2 comes a month after Summit shared a look at other endpoints. That earlier data drop linked ezutromid to a decline in muscle damage and an uptick in utrophin protein intensity levels. Together with the muscle inflammation readout, the data form the backbone of early efforts to show ezutromid is a disease-modifying therapy suited for use by all DMD patients.

Summit is short of making that argument conclusively. The next step is to post data from the full 48-week trial. Beyond that, Summit plans to move ezutromid into a pivotal study. 

The progress of those studies will be closely watched by the DMD community and Sarepta, which celebrated the approval of its drug targeting the disease by striking a deal with Summit. Sarepta paid $40 million upfront and committed to more than $500 million in milestones to secure the rights to ezutromid in Europe and some other markets.

Suggested Articles

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.